Lilly's retatrutide beats Ozempic on blood sugar and weight loss in head-to-head Phase 3 trial
Eli Lilly said its experimental drug retatrutide lowered A1C by an average of 2.2% at 80 weeks in adults with type 2 diabetes, compared with 1.8% for Novo Nordisk's Ozempic 2 mg, in the TRANSCEND-T2D-2 trial.